nach oben

Erschienen in:

06.04.2020 | Review

A focus on the association of Apol1 with kidney disease in children

verfasst von: Pepe M. Ekulu, Agathe B. Nkoy, Oyindamola C. Adebayo, Orly K. Kazadi, Michel N. Aloni, Fanny O. Arcolino, Rene M. Ngiyulu, Jean-Lambert E. Gini, François B. Lepira, Lamberthus P. Van den Heuvel, Elena N. Levtchenko

Erschienen in: Pediatric Nephrology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Individuals of African origin have an increased risk of developing various progressive chronic kidney diseases (CKD). This risk has been attributed to genetic variants (G1, G2) in apolipoprotein-L1 (APOL1) gene. In the pediatric population, especially in children affected by sickle cell disease (SCD), by human immunodeficiency virus (HIV), or with various glomerular diseases, APOL1 risk variants have been associated with the development of hypertension, albuminuria, and more rapid decline of kidney function. The present review focuses on existing APOL1-related epidemiological data in children with CKD. It also includes data from studies addressing racial disparities in CKD, the APOL1-related innate immunity, and the relationship between APOL1 and CKD and pathogenic pathways mediating APOL1-related kidney injury.

Cappuccio FP, Miller MA (2016) Cardiovascular disease and hypertension in sub-Saharan Africa: burden, risk and interventions. Intern Emerg Med 11:299–305PubMedPubMedCentral

Martins D, Tareen N, Norris KC (2002) The epidemiology of end-stage renal disease among African Americans. Am J Med Sci 323:65–71PubMed

Quaggin SE, George AL (2011) Apolipoprotein L1 and the genetic basis for racial disparity in chronic kidney disease. J Am Soc Nephrol 22:1955–1958PubMed

Moxey-Mims M (2018) Kidney disease in African American children: biological and nonbiological disparities. Am J Kidney Dis 72:S17–S21PubMed

Alves TP, Lewis J (2011) Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma. Clin Nephrol 74:72–77

Klag MJ (1997) End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA J Am Med Assoc 277:1293–1298

Siemens TA, Riella MC, Moraes TP, Riella CV (2018) APOL1 risk variants and kidney disease: what we know so far. Brazilian J Nephrol 40:388–402

Reidy KJ, Hjorten R, Parekh RS (2018) Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry. Curr Opin Pediatr 30:252–259PubMedPubMedCentral

Freedman BI, Limou S, Ma L, Kopp JB (2018) A key contributor to racial disparities in CKD. Am J Kidney Dis 7:S8–S16

10.

Kasembeli AN, Duarte R, Ramsay M, Saraladevi N (2015) African origins and chronic kidney disease susceptibility in the human immunodeficiency virus era. World J Nephrol 4:295–306PubMedPubMedCentral

11.

Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Morkrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA (2008) MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40:1175–1184PubMedPubMedCentral

12.

Kao WHL, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MA, Parekh RS (2008) MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40:1185–1192PubMed

13.

Madhavan SM, O’Toole JF (2014) The biology of APOL1 with insights into the association between APOL1 variants and chronic kidney disease. Clin Exp Nephrol 18:238–242PubMedPubMedCentral

14.

Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, Winkler CA, Bowden DW, Pollak MR (2010) The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 21:1422–1426PubMedPubMedCentral

15.

Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob A, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329:841–845PubMedPubMedCentral

16.

Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekel E, Bradman N, Wasser WG, Behar DM, Shorecki K (2010) Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128:345–350PubMedPubMedCentral

17.

Ray PE, Hu CAA (2011) Advances in our understanding of the pathogenesis of HIV-1 associated nephropathy in children. Futur Virol 6:883–894

18.

Thomson R, Genovese G, Canon C, Kovacsics D, Higgins MK, Carrington M, Winkler CA, Kopp J, Rotimi C, Adeyemo A, Doumatey A, Ayodo G, Alper SL, Pollak MR, Friedman DJ, Raper J (2014) Evolution of the primate trypanolytic factor APOL1. Proc Natl Acad Sci U S A 111:E2130–E2139PubMedPubMedCentral

19.

Friedman DJ, Pollak MR (2016) Apolipoprotein L1 and kidney disease in African Americans. Trends Endocrinol Metab 27:204–215PubMedPubMedCentral

20.

Pays E, Vanhollebeke B, Uzureau P, Lecordier L, Perez-Morga D (2014) The molecular arms race between African trypanosomes and humans. Nat Rev Microbiol 12:575–584PubMed

21.

Vanwalleghem G, Fontaine F, Lecordier L, Tebabi P, Klewe K, Nolan DP, Yamaryo-Botté Y, Botté C, Kremer A, Burkard GS, Rassow J, Roditi I, Pérez-Morga D, Pays E (2015) Coupling of lysosomal and mitochondrial membrane permeabilization in trypanolysis by APOL. Nat Commun 6:8078PubMedPubMedCentral

22.

Limou S, Nelson GW, Kopp JB, Winkler CA (2014) APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis 21:426–433PubMedPubMedCentral

23.

Lecordier L, Vanhollebeke B, Poelvoorde P, Tebabi P, Paturiaux-Hanocq F, Andris F, Lins L, Pays E (2009) C-Terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. PLoS Pathog 5:e1000685PubMedPubMedCentral

24.

Ma L, Divers J, Freedman BI (2019) Mechanisms of injury in APOL1 -associated kidney disease. Transplantation 103:487–492PubMedPubMedCentral

25.

Kozlitina J, Zhou H, Brown PN, Rohm RJ, Pan Y, Ayanoglu G, Du X, Rimmer E, Reilly DF, Roddy TP, Cully DF, Vogt TF, Blom D, Hoek M (2016) Plasma levels of risk-variant APOL1 do not associate with renal disease in a population-based cohort. J Am Soc Nephrol 27:3204–3219PubMedPubMedCentral

26.

Kopp JB, Nelson GW, Sampath K, Randall CJ, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA (2011) APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22:2129–2137PubMedPubMedCentral

27.

Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, Limou S, Sezgin E, Nelson GW, Fogo AB, Goetsch S, Kopp JB, Winkler CA, Naicker S (2015) APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J Am Soc Nephrol 11:2882–2890

28.

Divers J, Núñez M, High KP, Murea M, Rocco MV, Lijun M, Bowden DW, Hicks PJ, Spainhour M, Ornelles DA, Kleiboeker SB, Duncan K, Langefeld CD, Turner JL, Freedman BI (2013) JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int 84:1207–1213PubMedPubMedCentral

29.

Freedman BI, Kistler AL, Skewes-Cox P, Ganem D, Spainhour M, Turner J, Divers J, Langefeld CD, Murea M, Hicks PJ, Hemal AK, Snipes JA, Zhao L, Abend JR, Lyles DS, Ma L, Skorecki KL (2018) JC polyoma viruria associates with protection from chronic kidney disease independently from apolipoprotein L1 genotype in African Americans. Nephrol Dial Transplant 33:1960–1967PubMedPubMedCentral

30.

Nichols B, Jog P, Lee JH, Blackler D, Wilmot M, D'Agati V, Markowitz G, Kopp J, Alper SL, Pollak MR, Friedman DJ (2015) Innate immunity pathways regulate the nephropathy gene apolipoprotein L1. Kidney Int 87:332–342PubMed

31.

Obermoser G, Pascual V (2010) The interferon-α signature of systemic lupus erythematosus. Lupus 19:1012–1019PubMedPubMedCentral

32.

Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanocic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J (2017) A tripartite complex of suPAR, APOL1 risk variants and α v β 3 integrin on podocytes mediates chronic kidney disease. Nat Med 23:945–956PubMedPubMedCentral

33.

Langefeld CD, Comeau ME, Ng MCY, Guan M, Dimitrov L, Mudgal P, Spainhour MH, Julian BA, Edberg JC, Croker JA, Divers J, Hicks PJ, Bowden DW, Chan GC, Ma L, Palmer ND, Kimberly RP, Freedman BI (2018) Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1–second gene interactions. Kidney Int 94:599–607PubMedPubMedCentral

34.

Heymann J, Winkler CA, Hoek M, Susztak K, Kopp JB (2017) Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte. Nephrol Dial Transplant 32:i65–i70PubMedPubMedCentral

35.

Uzureau S, Coquerelle C, Vermeiren C, Uzureau P, Van Acker A, Pilotte L, Monteyne D, Acolty V, Vanhollebeke B, Van den Eynde B, Pérez-Morga D, Moser M, Pays E (2016) Apolipoproteins L control cell death triggered by TLR3/TRIF signaling in dendritic cells. Eur J Immunol 46:1854–1866PubMed

36.

Okamoto K, Rausch JW, Wakashin H, Fu Y, Chung JY, Dummer PD, Shin MK, Chandra P, Suzuki K, Shrivastav S, Rosenberg AZ, Hewitt SM, Ray PE, Noiri E, Le Grice SFJ, Hoek M, Han Z, Winkler CA, Kopp JB (2018) APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase R. Commun Biol 1:188PubMedPubMedCentral

37.

Ma L, Snipes JA, Murea M, Freedman BI, Chou JW, Hawkins GA, Langefeld CD, Bharadwaj MS, Molina AJ, Craddock AL, Miller LD, Cheng D, Weckerle A, Parks JS, Petrovic S, Hicks PJ, Hemal AK (2017) APOL1 renal-risk variants induce mitochondrial dysfunction. J Am Soc Nephrol 28:1093–1105PubMed

38.

Olabisi OA, Zhang J-Y, VerPlank L, Zahler N, DiBartolo S, Heneghan JF, Schlöndorff JS, Hee Suh J, Yan P, Alper SL, Friedman DJ, Pollak MR (2016) APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc Natl Acad Sci U S A 113:830–837PubMed

39.

Lan X, Jhaveri A, Cheng K, Wen H, Saleem MA, Mathieson PW, Mikulak J, Aviram S, Malhotra A, Skorecki K, Singhal PC (2014) APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Physiol 307:F326–F336

40.

Beckerman P, Bi-Karchin J, Park ASD, Qiu C, Dummer PD, Soomro I, Boustany-Kari CM, Pullen SS, Miner JH, Hu CAA, Rohacs T, Inoue K, Ishibe S, Saleem MA, Palmer MB, Cuervo AM, Kopp JB, Susztak K (2017) Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat Med 23:429–438PubMedPubMedCentral

41.

Kumar V, Paliwal N, Ayasolla K, Vashistha H, Jha A, Chandel N, Chowdhary S, Saleem MA, Malhotra A, Chander PN, Skorecki K, Singhal PC (2019) Disruption of APOL1-miR193a axis induces disorganization of podocyte actin cytoskeleton. Sci Rep 9:3582PubMedPubMedCentral

42.

Adeyemo A, Esezobor C, Solarin A, Abeyagunawardena A, Kari JA, El Desoky S, Greenbaum LA, Kamel M, Kallash M, Silva C, Young A, Hunley TE, de Jesus-Gonzalez N, Srivastava T, Gdadegesin R (2018) HLA-DQA1 and APOL1 as risk loci for childhood-onset steroid-sensitive and steroid-resistant nephrotic syndrome. Am J Kidney Dis 71:399–406PubMed

43.

Freedman BI, Skorecki K (2014) Gene–gene and gene–environment interactions in apolipoprotein L1 gene-associated nephropathy. Clin J Am Soc Nephrol 9:2006–2013PubMedPubMedCentral

44.

Hoy WE, Hughson MD, Kopp JB, Mott SA, Bertram JF, Winkler CA (2015) APOL1 risk alleles are associated with exaggerated age-related changes in glomerular number and volume in African-American adults: an autopsy study. J Am Soc Nephrol 26:3179–3189PubMedPubMedCentral

45.

Freedman BI, Langefeld CD, Lu L, Palmer ND, Smith SC, Bagwell BM, Hicks PJ, Xu J, Wagenknecht LE, Raffield LM, Register TC, Carr JJ, Bowden DW, Divers J (2015) APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int 87:176–181PubMed

46.

Ng DK, Robertson CC, Woroniecki RP, Limou S, Gillies CE, Reidy KJ, Winkler CA, Hingorani S, Gibson KL, Hjorten R, Cb S, Kopp JB, Moxey-Mims M, Furth SL, Warady BA, Kretzler M, Sedor JR, Kaskel FJ, Sampson MG (2017) APOL1-associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts. Nephrol Dial Transplant 32:983–990PubMed

47.

Purswani MU, Patel K, Winkler CA, Spector SA, Hazra R, Seage GR, Mofenson L, Karalius B, Scott GB, Van Dyke RB, Kopp JB (2016) Brief report: APOL1 renal risk variants are associated with chronic kidney disease in children and youth with perinatal HIV infection. J Acquir Immune Defic Syndr 73:63–68PubMedPubMedCentral

48.

Ekulu PM, Nkoy AB, Betukumesu DK, Aloni MN, Makulo JR, Sumaili EK, Mafuta EM, Elmonem MA, Arcolino FO, Kitetele FN, Lepira FB, Van den Heuvel LP, Levtchenko EN (2019) APOL1 risk genotypes are associated with early kidney damage in children in Sub-Saharan Africa. Kidney Int Rep 4:930–938PubMedPubMedCentral

49.

Kormann R, Jannot AS, Narjoz C, Ribeil JA, Manceau S, Delville M, Joste V, Prié D, Pouchot J, Thervet E, Courbebaisse M, Arlet JB (2017) Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target. Br J Haematol 179:323–335PubMed

50.

Geard A, Pule GD, Chemegni BC, Ngo Bitoungui VJ, Kengne AP, Chimusa ER, Wonkam A (2017) Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon HHS public access. Br J Haematol 178:629–639PubMedPubMedCentral

51.

Watanabe A, Feltran LS, Sampson MG (2019) Genetics of nephrotic syndrome presenting in childhood: core curriculum. Am J Kidney Dis 74:549–557PubMed

52.

Woroniecki RP, Ng DK, Limou S, Winkler CA, Reidy KJ, Mitsnefes M, Sampson MG, Wong CS, Warady BA, Furth SL, Kopp JB, Kaskel KJ (2016) Renal and cardiovascular morbidities associated with APOL1 status among African-American and non-African-American children with focal segmental glomerulosclerosis. Front Pediatr 4:426–433

53.

Guan I, Singer P, Frank R, Chorny N, Infante L, Sethna CB (2016) Role of race in kidney transplant outcomes in children with focal segmental glomerulosclerosis. Pediatr Transplant 20:790–797PubMed

54.

Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Bowden DW, Hicks PJ, PAlmer ND, Palanisamy A, Reeves-Daniel AM, Brown WM, Divers J (2016) APOL1 genotype and kidney transplantation outcomes from deceased African American donors. Transplantation 100:194–202PubMedPubMedCentral

55.

Lee BT, Kumar V, Williams TA, Bernhardy A, Dyer C, Conte S, Gnovese G, Ross MD, Friedman DJ, Gaston R, Milford E, Pollak MR, Chandraker A (2012) The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 12:1924–1928PubMedPubMedCentral

56.

Freedman BI, Moxey-Mims M (2018) The APOL1 long-term kidney transplantation outcomes network—APOLLO. Clin J Am Soc Nephrol 13:940–942PubMedPubMedCentral

Titel: A focus on the association of Apol1 with kidney disease in children
verfasst von: Pepe M. Ekulu
Agathe B. Nkoy
Oyindamola C. Adebayo
Orly K. Kazadi
Michel N. Aloni
Fanny O. Arcolino
Rene M. Ngiyulu
Jean-Lambert E. Gini
François B. Lepira
Lamberthus P. Van den Heuvel
Elena N. Levtchenko
Publikationsdatum: 06.04.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 4/2021
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-020-04553-z

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

A focus on the association of Apol1 with kidney disease in children

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

A toddler with severe hypercalcemia and pyelonephritis: Questions

Obesity, metabolic syndrome, and primary hypertension

Natural history of patients with infantile nephrolithiasis: what are the predictors of surgical intervention?

Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia

Nephron number and its determinants: a 2020 update

Acute necrotizing glomerulonephritis associated with COVID-19 infection: report of two pediatric cases

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie